Related Experiment Video
Updated: Jun 7, 2026
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
New parenteral anticoagulants in development.
Antonio Gómez-Outes1, Maria Luisa Suárez-Gea, Ramón Lecumberri
1Division of Pharmacology and Clinical Evaluation, Medicines for Human Use, Spanish Agency for Medicines and Health Care Products (AEMPS), Parque Empresarial Las Mercedes, Edificio 8, C/Campezo 1, Madrid, 28022, Spain. agomezo@aemps.es
Therapeutic Advances in Cardiovascular Disease
|November 4, 2010
Summary
Parenteral anticoagulants like heparin have drawbacks. Novel anticoagulants in development aim to improve safety and efficacy for preventing and treating thromboembolic diseases.
Area of Science:
- Pharmacology and clinical development of anticoagulant therapies.
- Thromboembolic disease prevention and treatment strategies.
Background:
- Established parenteral anticoagulants such as unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), fondaparinux, and direct thrombin inhibitors are effective but present challenges.
- Drawbacks include the need for monitoring (UFH), renal clearance issues (LMWH, fondaparinux, hirudins), and lack of specific antidotes for some agents.
Purpose of the Study:
- To review the pharmacology, clinical study results, and ongoing trials of novel parenteral anticoagulants.
- To evaluate the potential advantages and disadvantages of these new agents compared to existing therapies.
Main Methods:
- Review of existing literature on parenteral anticoagulants.
- Analysis of pharmacological data and clinical trial outcomes for novel agents.
- Discussion of ongoing and planned clinical investigations.
Main Results:
- A wide range of novel parenteral anticoagulants are under development, targeting various factors in the coagulation cascade (e.g., FXa, FIIa, FXIa, FIXa, FVIIIa, FVIIa/TF, FVa).
- These include indirect FXa inhibitors, direct FXa inhibitors, direct FIIa inhibitors, and dual inhibitors, among others.
- These agents show potential to overcome limitations of current anticoagulants.
Conclusions:
- Novel parenteral anticoagulants offer promising alternatives to current therapies.
- Further clinical evaluation is necessary to establish their safety, efficacy, and place in managing thromboembolic disorders.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:28Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
01:29Drug Delivery: Parenteral Route
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
01:24Parenteral Anesthetics: Overview
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.